Updates
** Shares of drugmaker Eli Lilly LLY.N fall 8.6% to $821.62
** CVS Health CVS.N says it plans to drop LLY's obesity drug Zepbound from the list of medicines it covers for reimbursement
** CVS says it would drop coverage from July 1, but keep reimbursing for rival GLP-1 weight-loss drug Wegovy after negotiating a more favorable price from Novo Nordisk NOVOb.CO
** Q1 sales of Zepbound of $2.31 billion came in slightly below analysts' estimates of $2.33 billion, as per data compiled by LSEG
** Co also cuts annual adj. profit forecast to between $20.78 per share and $22.28 per share from $22.50 per share to $24 per share previously
** Including session's moves, LLY up 7.9% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。